Have a personal or library account? Click to login
Formulation development of an albendazole self-emulsifying drug delivery system (SEDDS) with enhanced systemic exposure / Razvoj samoemulzifirajućeg sustava za isporuku albendazola (SEDDS) s pojačanom sistemskom apsorpcijom Cover

Formulation development of an albendazole self-emulsifying drug delivery system (SEDDS) with enhanced systemic exposure / Razvoj samoemulzifirajućeg sustava za isporuku albendazola (SEDDS) s pojačanom sistemskom apsorpcijom

Open Access
|Jan 2013

References

  1. 1. J. R. Robinson, Introduction: semi-solid formulations for oral drug delivery, Bull. Tech. Gattefosse 89 (1996) 11-13.
  2. 2. A. K. Meena, D. V. Ratnam, G. Chandraiah, D. D. Ankola, P. R. Rao and M. N. Kumar, Oral nanoparticulate atorvastatin calcium is more efficient and safe in comparison to Lipicure in treating hyperlipidemia, Lipids 43 (2008) 231-241; DOI: 10.1007/s11745-007-3142-5.10.1007/s11745-007-3142-5
  3. 3. D. V. Ratnam, G. Chandraiah, A. K. Meena, P. Ramarao and M. N. Kumar, The co-encapsulated antioxidant nanoparticles of ellagic acid and coenzyme Q10 ameliorate hyperlipidemia in high fat diet fed rats, J. Nanosci. Nanotechnol. 9 (2009) 6741-6746.10.1166/jnn.2009.1461
  4. 4. C. W. Pouton, Effects of the inclusion of a model drug on the performance of self-emulsifying formulations, J. Pharm. Pharmacol. 37 (1985) Suppl. 12:1P; DOI: 10.1111/j.2042-7158.1985.tb14073.
  5. 5. C. W. Pouton, Self-emulsifying drug delivery systems: assessment of the efficiency of emulsification, Int. J. Pharm. 27 (1985) 335-348; DOI: 10.1016/ 0378-5173(85)90081-X.
  6. 6. C. W. Pouton, Formulation of self-emulsifying drug delivery systems, Adv. Drug. Deliv. Rev. 25 (1997) 47-58; DOI: 10.1016/S0169-409X(96)00490-5.10.1016/S0169-409X(96)00490-5
  7. 7. H. Shen and M. Zhong, Preparation and evaluation of self-microemulsifying drug delivery systems (SMEDDS) containing atorvastatin, J. Pharm. Pharmacol. 58 (2006) 1183-1191; DOI: 10.1211/jpp.58.9.0004.10.1211/jpp.58.9.0004
  8. 8. N. H. Shah, M. T. Carvajal, C. I. Patel, M. H. Infeld and A. W. Malick, Self-emulsifying drug delivery systems (SEDDS) with polyglycolyzed glycerides for improving in vitro dissolution and oral absorption of lipophilic drugs, Int. J. Pharm. 106 (1994) 15-23; DOI: 10.1016/0378-5173(94)90271-2.10.1016/0378-5173(94)90271-2
  9. 9. T. R. Kommuru, B. Gurley, M. A. Khan and I. K. Reddy, Self-emulsifying drug delivery systems (SEDDS) of coenzyme Q10: formulation development and bioavailability assessment, Int. J. Pharm. 212 (2001) 233-246; DOI: 10.1016/ S0378-5173(00)00614-1.
  10. 10. A. A. Kale and V. B. Patravale, Design and evaluation of self-emulsifying drug delivery systems (SEDDS) of nimodipine, AAPS Pharm. Sci. Tech. 9 (2008) 191-196; DOI: 10.1208/s12249-008-9037-9.10.1208/s12249-008-9037-9
  11. 11. J. I. Tang, J. Sun and Z. G. He, Self-emulsifying drug delivery systems: strategy for improving oral delivery of poorly soluble drugs, Curr. Drug Therapy 2 (2007) 85-93.
  12. 12. P. Gao, B. D. Rush, W. P. Pfund, T. Huang, J. M. Bauer W. Morozowich, M. S. Kuo and M. J. Hageman, Development of a supersaturable SEDDS (S-SEDDS) formulation of paclitaxel with improved oral bioavailability, J. Pharm. Sci. 87 (2003) 2386-2398; DOI: 10.1002/jps.10511.10.1002/jps.10511
  13. 13. G. C. Cook, Use of benzimidazole chemotherapy in human helminthiases: Indications and efficacy, Parasitol. Today 6 (1990) 133-136; DOI: 10.1016/0169-4758(90)90232-S.10.1016/0169-4758(90)90232-S
  14. 14. E. Galia, J. Horton and J. B. Dressman, Albendazole generics: a comparative in vitro study, Pharm. Res. 16 (1999) 1871-1875; DOI: 10.1023/A:1018907527253.10.1023/A:1018907527253
  15. 15. I. M. Rigter, H. G. Schipper, R. P. Koopmans, H. J. M. Van Kan, H. W. Frijlink, P. A. Kager and H. J. Guchelaar, Relative bioavailability of three newly developed albendazole formulations: a randomized crossover study with healthy volunteers, Antimicrob. Agents Chemother. 48 (2004) 1051-1054; DOI: 10.1128/ AAC. 48.3. 1051-1054.2004.
  16. 16. C. T. Dollery, Albendazole, in Therapeutic Drugs, 2nd ed., Churchill Livingstone, Edinburgh 1999, pp. 184-188.
  17. 17. J. J. García, F. Bolas and J. J. Torrado, Bioavailability and efficacy characteristics of two different oral liquid formulations of albendazole, Int. J. Pharm. 250 (2003) 351-358; DOI: 10.1016/S0378-5173(02)00559-8.10.1016/S0378-5173(02)00559-8
  18. 18. S. Torrado, S. Torrado, R. Cadorniga and J. J. Torrado, Formulation parameters of albendazole solution, Int. J. Pharm. 140 (1996) 45-50; DOI: 10.1016/0378-5173(96)04545-0.10.1016/0378-5173(96)04545-0
  19. 19. S. Torrado, M. L. López, G. Torrado, F. Bolás, S. Torrado and R. Cadórniga, A novel formulation of albendazole solution: oral bioavailability and efficacy evaluation, Int. J. Pharm. 156 (1997) 181-187; DOI: 10.1016/S0378-5173(97)00204-4.10.1016/S0378-5173(97)00204-4
  20. 20. P. A. Redondo, A. I. Alvarez, J. L. García, C. Villaverde and J. G. Prieto, Influence of surfactants on oral bioavailability of albendazole based on the formation of the sulphoxide metabolites in rats, Biopharm. Drug Dispos. 19 (1998) 65-70.10.1002/(SICI)1099-081X(199801)19:1<65::AID-BDD76>3.0.CO;2-8
  21. 21. H. Wen, R. R. New, M. Muhmut, J. H. Wang, Y. H. Wang, J. H. Zhang, Y. M. Shao and P. S. Craig, Pharmacology and efficacy of liposome entrapped albendazole in experimental secondary alveolar echinococcosis and effect of co-administration with cimetidine, Parasitology 113 (1996) 111-121; DOI: 10.1017/S003118200006635X.10.1017/S003118200006635X
  22. 22. S. Torrado, S. Torrado, J. J. Torrado and R. Cadórniga, Preparation, dissolution and characterization of albendazole solid dispersion, Int. J. Pharm. 140 (1996) 247-250; DOI: 10.1016/0378-5173(96)04586-3.10.1016/0378-5173(96)04586-3
  23. 23. M. L. Lopez, S. Torrado, S. Torrado, A. R. Martínez and F. Bolás, Improvement of albendazole efficacy against enteral, but not against parenteral stages of Trichinella spiralis by preparing solid dispersions in polyvinylpyrrolidone, Chemotherapy 43 (1997) 430-435; DOI: 10.1159/000239602.10.1159/000239602
  24. 24. R. Kalaiselvan, G. P. Mohanta, K. Kannan, P. K. Manna and R. Manavalan, Optimization of drug-polymer mixing ratio in albendazole-polyvinylpyrrolidone solid dispersion by moisture absorption studies, Acta. Pharm. Sci. 48 (2006) 141-151.
  25. 25. J. A. Castillo, J. Palomo-Canales, J. J. Garcia, J. L. Lastres, F. Bolas and J. J. Torrado, Preparation and characterization of albendazole β-cyclodextrin complexes, Drug. Dev. Ind. Pharm. 25 (1999) 1241-1248; DOI: 10.1081/DDC-100102294.10.1081/DDC-100102294
  26. 26. G. Piel, B. Evrard, T. Van Hees, G. Llabres and L. Delattre, Development of a parenteral and of an oral formulation of albendazole with cyclodextrins, STP. Pharma. Sci. 9 (1999) 257-260.
  27. 27. T. Mukherjee and F. M. Plakogiannis, Development and oral bioavailability assessment of a supersaturated self-microemulsifying drug delivery system (SMEDDS) of albendazole, J. Pharm. Pharmacol. 62 (2010) 1112-1120; DOI: 10.1111/j.2042-7158.2010.01149.x.10.1111/j.2042-7158.2010.01149.x
  28. 28. C. W. Pouton, Lipid formulations for oral administration of drugs: non- emulsifying, self-emulsifying and self-microemulsifying drug delivery systems, Eur. J. Pharm. Sci. 11 (2000) S93-S98; DOI: 10.1016/S0928-0987(00)00167-6.10.1016/S0928-0987(00)00167-6
  29. 29. V. Borhade, H. Nair and D. Hegde, Design and evaluation of self-microemulsifying drug delivery system (SMEDDS) of tacrolimus, AAPS Pharm. Sci. Tech. 9 (2008) 13-21; DOI: 10.1208/s12249-007-9014-8.10.1208/s12249-007-9014-8
  30. 30. K. Sharma, M. Kandaswamy, C. Mithra, A. K. Meena, S. Giri, S. Rajagopal and R. Mullangi, Highly sensitive LC-MS/MS-ESI method for simultaenous quantitation of albendazole and ricobendazole in rat plasma and its application to a rat pharmacokinetic study, Biomed. Chromatogr. 26 (2011) 247-255; DOI: 10.1002/bmc.1654.10.1002/bmc.165421633966
  31. 31. H. Jung, M. Hurtado, M. Sanchez, M. T. Medina and J. Sotelo, Clinical pharmacokinetics of albendazole in patients with brain cysticercosis, J. Clin. Pharmacol. 32 (1992) 28-31.10.1002/j.1552-4604.1992.tb03783.x1740534
  32. 32. J. Sotelo and H. Jung, Pharmacokinetic optimization of treatment of neurocysticercosis, Clin. Pharmacokinet. 34 (1998) 503-515.10.2165/00003088-199834060-000069646011
DOI: https://doi.org/10.2478/v10007-012-0031-0 | Journal eISSN: 1846-9558 | Journal ISSN: 1330-0075
Language: English
Page range: 563 - 580
Published on: Jan 15, 2013
Published by: Croatian Pharmaceutical Society
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year
Related subjects:

© 2013 , published by Croatian Pharmaceutical Society
This work is licensed under the Creative Commons License.